WHC is still in active development. Read this to understand our approach.
depiction of JUKMAYKVHWKRKY-UHFFFAOYSA-N.svg
tripsit

3,4-ctmp

Check on tripsit

psychonaut

3,4-CTMP

Check on psychonaut

isomerdesign

3,4-CTMP

Check on isomerdesign

druglab

3,4-CTMP

Check on druglab

drugmap

Erythro-3,4-dichloro...

Check on drugmap

Data

InChI: InChI=1S/C14H17Cl2NO2/c1-19-14(18)13(12-4-2-3-7-17-12)9-5-6-10(15)11(16)8-9/h5-6,8,12-13,17H,2-4,7H2,1H3

Synonyms: 3,4-CTMP,3,4-dichloromethylphenidate,3,4-Dichloromethylphenidate,methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate,UNII-1MM9174NWD,Methyl alpha-(3,4-dichlorophenyl)-2-piperidineacetate,METHYL .ALPHA.-(3,4-DICHLOROPHENYL)-2-PIPERIDINEACETATE,Methyl (2R)-(3,4-dichlorophenyl)[(2R)-2-piperidinyl]acetate,Methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate,2-PIPERIDINEACETIC ACID, .ALPHA.-(3,4-DICHLOROPHENYL)-, METHYL ESTER,CHEMBL1179011,Methyl-(3,4-dichlorophenyl)[(2S)-2-piperidinyl]acetate,(R)-methyl 2-(3,4-dichlorophenyl)-2-((R)-piperidin-2-yl)acetate,CHEMBL537654,2-Piperidineacetic acid, alpha-(3,4-dichlorophenyl)-, methyl ester,DTXSID301029379,2-Piperidineacetic acid, alpha-(3,4-dichlorophenyl)-, methyl ester, (alphaR,2R)-,34ctmp,3,4-Ctmp,3,4-Dcmp,1MM9174NWD,(+/-)-threo-3,4-Dichloromethylphenidate,(alphaR,2R)-alpha-(3,4-Dichlorophenyl)-2-piperidineacetic acid methyl ester,F7LN3N6ZLA,210776-65-1,1364331-88-3,3,4-DCMP,3,4-DICHLOROMETHYLPHENIDATE, R,R-,UNII-F7LN3N6ZLA,BDBM50327157,1400742-68-8,methyl (2R)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetate,ZINC28645396,2-PIPERIDINEACETIC ACID, .ALPHA.-(3,4-DICHLOROPHENYL)-, METHYL ESTER, (.ALPHA.R,2R)-, Erythro-3,4-Dichloromethylphenidate HCl

Estimated data

Solubility: -3.551 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 77.5% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.